Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma

Next Previous
Trial Profile

A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Elimusertib (Primary) ; Gemcitabine (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant-mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Penile cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions

Most Recent Events

  • 10 Jun 2025 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
  • 10 Jun 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Jun 2026.
  • 01 Jun 2024 Planned End Date changed from 31 Dec 2024 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top